Business
OTC Markets Group Welcomes Newly Verified OTCQB Companies – Dec. 31
OTC Markets Group Welcomes Newly Verified OTCQB Companies – Dec. 31.
About this update from As-ip Tech, Inc.
[{"type":"text","content":"OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced the following companies are verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, effective December 31, 2014: AS-IP Tech, Inc. (OTCQB: IPTK) – AS-IP Tech owns intellectual property named SafeCell, which comprises a proof of concept and approved patents in Australia and China. The concept is based on turning a personal electronic device into a wireless communicator utilizing a secondary communications port such as Bluetooth or USB rather than WiFi or GSM. The in-flight messaging has been licensed to ASiQ Limited for airline and business jet communications, and which ASiQ is marketing under the brand name “BizjetMobile.” The user interface is an Application (“App”) that connects a user’s mobile device to an on-board Bluetooth network and utilizes the inexpensive narrowband satellite links provided by Iridium and Inmarsat. Inmarsat is the predominant airline satellite network outside the USA, and Iridium holds the same status on corporate aircraft globally.AS-IP Tech is approved to continue trading on OTCQB.HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) – HedgePath Pharmaceuticals is a biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers. HedgePath Pharmaceuticals is approved to continue trading on OTCQB. Lixte Biotechnology, Inc. (OTCQB: LIXT) – Lixte Biotechnology Holdings, Inc. is a clinical-stage public pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. Lixte Biotechnology is approved to continue trading on OTCQB. Nephros, Inc. (OTCQB: NEPH) – Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Its filters, which ...